FDA clears Rcadias coronary artery assessment system
The FDA has granted Rcadia Medical Imaging’s latest COR Analyzer System 510(k) clearance, opening the way for Rcadia to release the third version of its coronary artery assessment software.
According to Rcadia, the newest clinical decision support system can now be used to detect stenotic lesions in coronary branch vessels, in addition to main arteries, in patients with suspected coronary artery disease undergoing CT angiography. Rcadia, which is headquartered in Auburndale, Mass., develops computer-aided detection programs, largely geared towards emergency use.
According to Rcadia, the newest clinical decision support system can now be used to detect stenotic lesions in coronary branch vessels, in addition to main arteries, in patients with suspected coronary artery disease undergoing CT angiography. Rcadia, which is headquartered in Auburndale, Mass., develops computer-aided detection programs, largely geared towards emergency use.